#USA #New York #Securities Fraud #Pomerantz LLP #Capricor Therapeutics

Pomerantz Law Firm Investigates Capricor Therapeutics Amid Potential Fraud Allegations

Pomerantz LLP, a well-respected law firm known for its prowess in corporate securities litigation, has initiated an investigation regarding claims from investors of Capricor Therapeutics, Inc. (NASDAQ: CAPR). This action comes in light of significant declines in the company's stock values, raising questions about whether Capricor and its executives may have engaged in illegal business practices or securities fraud.

On May 5, 2025, Capricor made headlines with a press release that detailed developments concerning its Biologics License Application (BLA) for deramiocel, a pioneering cell therapy aimed at treating patients suffering from Duchenne muscular dystrophy (DMD) cardiomyopathy. The press release highlighted that following a mid-cycle review meeting with the U.S. Food and Drug Administration (FDA), the agency signaled its intention to convene an advisory committee meeting regarding the BLA.

However, shortly after this announcement, investors reacted negatively, causing a substantial decline in share price. By May 6, 2025, the stock price had plummeted by 29.13%, or $3.00 per share, closing at $7.30. This steep drop raised alarms about potential undisclosed contractual issues or risks associated with deramiocel.

The situation worsened on June 20, 2025, when an article published in STAT reported that the head of the FDA unit responsible for reviewing deramiocel had canceled the advisory committee meeting amid concerns over the drug’s safety and efficacy. Consequently, Capricor's stock took another hit, losing an additional 30.82% and closing at $8.26 per share. This series of events has led to considerable speculation about the company's transparency and adherence to regulatory protocols.

Pomerantz LLP encourages affected investors to reach out to their office for consultation. Danielle Peyton, representing the firm, stated that they are committed to protecting the rights of investors who might have been misled by the actions or statements of Capricor's management. Interested parties are urged to contact her directly at [email protected] or call 646-581-9980, extension 7980.

Founded more than 85 years ago by the distinguished Abraham L. Pomerantz, often recognized as a pioneer in the realm of class action lawsuits, the firm has a storied history in championing the rights of investors. Pomerantz has successfully recovered numerous multi-million dollar awards for investors affected by securities fraud and corporate misconduct.

This ongoing investigation reflects the firm’s commitment to ensuring that investors are not left vulnerable to the consequences of corporate malfeasance. With Capricor's recent downturn, the need for transparency and accountability in the healthcare sector becomes ever more pronounced.

As the investigation unfolds, it remains imperative for current and former investors to stay apprised of developments surrounding Capricor Therapeutics and to consider their options moving forward. Investors are reminded that legal recourse may be available for those affected by the considerable financial losses resulting from these unsettling events.